JPWO2020128873A5 - - Google Patents

Claims (16)

An accessory for an injection device having a needle cap, said accessory comprising:
a body portion comprising a recess adapted to receive said injection device;
A cover coupled to the body portion, the cover having an open position exposing the recess to receive the injection device and an open position at least partially closing the recess to secure the injection device to the body portion. a cover pivotable between a retaining closed position;
A capping device comprising grips, said capping device having an expanded configuration that allows said needle cap to pass between said gripping portions, said gripping portions holding said needle cap, said injection device a retracting configuration for at least partially removing the needle cap from
The cover and the decapping device are operatively coupled to each other such that the decapping device transitions from the expanded configuration to the contracted configuration when the cover is moved from the open position toward the closed position. Connected accessories. 2. The accessory of claim 1, wherein the cap remover is arranged to return to the expanded configuration to release the needle cap once the cover reaches the closed position. the gripper is adapted to hold the needle cap when the decapping device is in the contracted configuration and offset from the needle cap when the decapping device is in the expanded configuration; 3. An accessory according to claim 1 or claim 2, comprising at least one movable element. The at least one movable element is formed from a flexible elastic material, and the flexible elastic material adjusts the at least one movable element to a position where the gripper holds the needle cap and the needle. 4. An accessory according to claim 3, movable between a position in which a cap can be passed between said grips. the at least one movable element is configured to bend between a position in which the gripping portion retains the needle cap and a position in which the needle cap can pass between the gripping portions; 5. An accessory according to claim 4. 4. The claim further comprising at least one decapper cam positioned to interact with at least one decapper cam surface to transition the decapper from the expanded configuration to the retracted configuration. An accessory according to claim 1 or claim 2 . 7. Accessory according to claim 6 , wherein the at least one cap remover cam is coupled to or provided on the at least one movable element. 7. The accessory of claim 6 , wherein the cap remover cam surface is coupled to or provided on the body portion. the at least one decapper cam surface transitions the decapper from the expanded configuration to the retracted configuration as the decapper cam moves past the decapper cam surface; 7. The accessory of claim 6 , arranged to interact with the cap remover cam to return to the expanded configuration. 7. The accessory of claim 6 , wherein the at least one decapper cam and the at least one decapper cam surface are offset from each other when the cover is in the open position. Movement of the cover from the open position to the closed position moves the cap remover cam into engagement with the cap remover cam surface such that the cap remover moves from the expanded configuration to the contracted configuration. 7. An accessory according to claim 6 , transitioning to. 3. An accessory according to claim 1 or claim 2, wherein the gripping portion comprises at least one gripping end shaped to match an outer surface of the needle cap. the gripper is adapted to hold the needle cap when the decapping device is in the contracted configuration and offset from the needle cap when the decapping device is in the expanded configuration; 3. An accessory according to claim 1 or claim 2, comprising a pair of movable elements. 3. A system for performing an injection, said system comprising said injection device having said needle cap and an accessory according to claim 1 or claim 2 . The injection device
Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency poisoning, pain, thrombosis, infections, diabetes, diabetic retinopathy, acute coronary syndrome, angina pectoris, myocardial infarction, atheromatous artery Antibodies (monoclonal antibodies, ustekinumab, golimumab, infliximab) for use in the treatment or prevention of sclerosis, cancer, macular degeneration, allergies, hay fever, inflammation, anemia, or myelodysplasia, or for the development of protective immunity , guselkumab, silkumab, adalimumab, rituximab, tocilizumab, centolizumab, centolizumab pegol, sarilumab, secukinumab, ixekizumab, or biosimilar versions thereof), etanercept, abatacept, anakinra, epoetin alfa, darbepoetin alfa, epoetin beta- Methoxypolyethylene glycol, peginesatide, hormones, antitoxins, pain control substances, thrombosis control substances, infection control or elimination substances, peptides, proteins, human insulin or human insulin analogues or derivatives, polysaccharides, DNA, RNA , enzymes, oligonucleotides, anti-allergic drugs, antihistamines, anti-inflammatory drugs, corticosteroids, disease-modifying antirheumatic drugs, erythropoietin, or vaccines . system. Antibodies (monoclonal antibodies, ustekinumab, golimumab, infliximab, guselkumab, silkumab, adalimumab, rituximab, tocilizumab, centolizumab, centolizumab pegol, sarilumab, secukinumab) to human subjects by using the system according to claim 14 , ixekizumab, or biosimilar versions thereof), etanercept, abatacept, anakinra, epoetin alfa, darbepoetin alfa, epoetin beta-methoxy polyethylene glycol, peginesatide, hormones, antitoxins, pain control agents, thrombosis control agents, infection disease control or elimination substances, peptides, proteins, human insulin or human insulin analogues or derivatives, polysaccharides, DNA, RNA, enzymes, oligonucleotides, anti-allergic drugs, antihistamines, anti-inflammatory drugs, corticosteroids, Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, ulcerative colitis, hormone deficiency poisoning, pain, thrombosis, infection by delivery of a substance selected from the group consisting of disease-modifying antirheumatic drugs, erythropoietin, or vaccines diabetes, diabetic retinopathy, acute coronary syndrome, angina pectoris, myocardial infarction, atherosclerosis, cancer, macular degeneration, allergy, hay fever, inflammation, anemia, or myelodysplasia or an injection device for use in developing protective immunity.